Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NKG2D CAR-NK Cells in Locally Advanced Pancreatic Cancer
NCT06478459Phase 1Recruiting
- Sponsor
- Zhejiang University
- Start
- Jun 2024
- Primary completion
- Jun 2025
- Modality
- Gene Editing, Gene Silencing, Lymphokine-Activated Killer Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of NKG2D CAR-NK in pancreatic cancer (PC), sponsored by Zhejiang University. Primary endpoints: Maximum tolerated dose at 28 days and Dose limiting toxicity at 2 years. Started Jun 2024; status: recruiting.
02
Drugs
NKG2D CAR-NK
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT06478459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06478459.